JP2020513804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513804A5 JP2020513804A5 JP2019549574A JP2019549574A JP2020513804A5 JP 2020513804 A5 JP2020513804 A5 JP 2020513804A5 JP 2019549574 A JP2019549574 A JP 2019549574A JP 2019549574 A JP2019549574 A JP 2019549574A JP 2020513804 A5 JP2020513804 A5 JP 2020513804A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- tau
- pharmaceutical composition
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022164041A JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2024055230A JP2024088689A (ja) | 2017-03-16 | 2024-03-29 | 抗ｐｈｆ－タウ抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472214P | 2017-03-16 | 2017-03-16 | |
| US62/472,214 | 2017-03-16 | ||
| PCT/US2018/022782 WO2018170351A1 (en) | 2017-03-16 | 2018-03-16 | Anti-phf-tau antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164041A Division JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513804A JP2020513804A (ja) | 2020-05-21 |
| JP2020513804A5 true JP2020513804A5 (enExample) | 2021-04-15 |
| JP7159185B2 JP7159185B2 (ja) | 2022-10-24 |
Family
ID=63521020
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549574A Active JP7159185B2 (ja) | 2017-03-16 | 2018-03-16 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2022164041A Withdrawn JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2024055230A Withdrawn JP2024088689A (ja) | 2017-03-16 | 2024-03-29 | 抗ｐｈｆ－タウ抗体及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164041A Withdrawn JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2024055230A Withdrawn JP2024088689A (ja) | 2017-03-16 | 2024-03-29 | 抗ｐｈｆ－タウ抗体及びその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10766953B2 (enExample) |
| EP (1) | EP3596119A4 (enExample) |
| JP (3) | JP7159185B2 (enExample) |
| KR (2) | KR102695287B1 (enExample) |
| CN (2) | CN117209599A (enExample) |
| AR (1) | AR111288A1 (enExample) |
| AU (1) | AU2018234709B2 (enExample) |
| CA (1) | CA3055598A1 (enExample) |
| CL (1) | CL2019002566A1 (enExample) |
| EA (1) | EA201992038A1 (enExample) |
| IL (2) | IL268700B2 (enExample) |
| JO (1) | JOP20180021A1 (enExample) |
| MA (1) | MA47789A (enExample) |
| MX (2) | MX2019010922A (enExample) |
| MY (1) | MY205672A (enExample) |
| PH (1) | PH12019501973A1 (enExample) |
| SG (1) | SG11201907754RA (enExample) |
| TW (1) | TWI771389B (enExample) |
| UA (1) | UA128385C2 (enExample) |
| UY (2) | UY37635A (enExample) |
| WO (1) | WO2018170351A1 (enExample) |
| ZA (2) | ZA202101318B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2794654T3 (da) * | 2011-12-20 | 2019-08-05 | Janssen Biotech Inc | Anti-phf-tau-antistoffer og deres anvendelser |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| DK3452507T3 (da) | 2016-05-02 | 2022-11-14 | Prothena Biosciences Ltd | Tau-immunoterapi |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
| UA129617C2 (uk) | 2017-10-16 | 2025-06-18 | Еісаі Р Енд Д Менеджмент Ко., Лтд. | Антитіло до тау та його застосування |
| AU2019232631A1 (en) | 2018-03-05 | 2020-09-24 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EA202192888A1 (ru) * | 2019-05-31 | 2022-03-23 | Эли Лилли Энд Компани | Соединения и способы нацеливания на тау человека |
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| BR112022020410A2 (pt) * | 2020-04-08 | 2023-01-03 | Janssen Biotech Inc | Anticorpos anti-phf-tau e usos dos mesmos |
| AU2021309020A1 (en) * | 2020-07-14 | 2023-03-09 | Janssen Pharmaceutica Nv | Blood-based assay for detecting tauopathy or amyloidogenic disease |
| KR20230097110A (ko) * | 2020-10-26 | 2023-06-30 | 얀센 파마슈티카 엔.브이. | 항-타우 항체의 안전한 투여 방법 |
| CA3199806A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Methods of reducing tau in human subjects |
| AU2022222134A1 (en) * | 2021-02-19 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Anti-pt217 tau antibody |
| CA3214310A1 (en) | 2021-03-26 | 2022-09-29 | Rupesh Nanjunda | Anti-tau antibodies and uses thereof |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| CN116948024B (zh) * | 2023-09-14 | 2024-02-06 | 北京凯祥弘康生物科技有限公司 | 抗Tau蛋白的捕获抗体 |
| CN116948023B (zh) * | 2023-09-14 | 2024-02-09 | 北京凯祥弘康生物科技有限公司 | Tau蛋白抗体及其应用 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1993008302A1 (en) | 1991-10-25 | 1993-04-29 | Itt Automotive Europe Gmbh | Monoclonal antibodies directed against the microtubule-associated protein tau |
| AU698383B2 (en) | 1993-12-21 | 1998-10-29 | Innogenetics N.V. | Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications |
| ATE234324T1 (de) | 1994-07-29 | 2003-03-15 | Innogenetics Nv | Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| ES2567198T3 (es) * | 2003-01-24 | 2016-04-20 | Applied Molecular Evolution, Inc. | Antagonistas de la IL-1 beta humana |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| WO2005079479A2 (en) * | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP2057193B1 (en) | 2006-08-04 | 2013-12-18 | Novartis AG | Ephb3-specific antibody and uses thereof |
| JP2010235447A (ja) | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
| WO2010045340A1 (en) | 2008-10-14 | 2010-04-22 | Centocor Ortho Biotech Inc. | Methods of humanizing and affinity-maturing antibodies |
| DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| WO2010144711A2 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| US8912355B2 (en) | 2009-09-29 | 2014-12-16 | University Of Ottawa Heart Institute | Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
| US8580714B2 (en) | 2009-10-14 | 2013-11-12 | Janssen Biotech, Inc. | Methods of affinity maturing antibodies |
| BR112012025730B1 (pt) * | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
| EP2625198B1 (en) | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
| US8940272B2 (en) * | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| DK2794654T3 (da) * | 2011-12-20 | 2019-08-05 | Janssen Biotech Inc | Anti-phf-tau-antistoffer og deres anvendelser |
-
2017
- 2017-03-16 JO JOP/2018/0021A patent/JOP20180021A1/ar unknown
-
2018
- 2018-03-15 TW TW107108890A patent/TWI771389B/zh active
- 2018-03-16 EP EP18767083.1A patent/EP3596119A4/en active Pending
- 2018-03-16 SG SG11201907754RA patent/SG11201907754RA/en unknown
- 2018-03-16 JP JP2019549574A patent/JP7159185B2/ja active Active
- 2018-03-16 KR KR1020237037321A patent/KR102695287B1/ko active Active
- 2018-03-16 CN CN202310854848.XA patent/CN117209599A/zh active Pending
- 2018-03-16 EA EA201992038A patent/EA201992038A1/ru unknown
- 2018-03-16 CA CA3055598A patent/CA3055598A1/en active Pending
- 2018-03-16 IL IL268700A patent/IL268700B2/en unknown
- 2018-03-16 WO PCT/US2018/022782 patent/WO2018170351A1/en not_active Ceased
- 2018-03-16 AU AU2018234709A patent/AU2018234709B2/en active Active
- 2018-03-16 IL IL310464A patent/IL310464A/en unknown
- 2018-03-16 MX MX2019010922A patent/MX2019010922A/es unknown
- 2018-03-16 UA UAA201910307A patent/UA128385C2/uk unknown
- 2018-03-16 US US15/923,011 patent/US10766953B2/en active Active
- 2018-03-16 KR KR1020197028728A patent/KR102597462B1/ko active Active
- 2018-03-16 AR ARP180100620A patent/AR111288A1/es unknown
- 2018-03-16 UY UY0001037635A patent/UY37635A/es not_active Application Discontinuation
- 2018-03-16 CN CN201880018431.7A patent/CN110799531B/zh active Active
- 2018-03-16 MA MA047789A patent/MA47789A/fr unknown
- 2018-03-16 MY MYPI2019005282A patent/MY205672A/en unknown
-
2019
- 2019-08-28 PH PH12019501973A patent/PH12019501973A1/en unknown
- 2019-09-09 CL CL2019002566A patent/CL2019002566A1/es unknown
- 2019-09-13 MX MX2024015440A patent/MX2024015440A/es unknown
-
2020
- 2020-08-06 US US16/986,615 patent/US11365244B2/en active Active
-
2021
- 2021-02-26 ZA ZA2021/01318A patent/ZA202101318B/en unknown
-
2022
- 2022-05-18 US US17/747,785 patent/US20230047413A1/en not_active Abandoned
- 2022-10-12 JP JP2022164041A patent/JP2022191383A/ja not_active Withdrawn
-
2023
- 2023-12-12 ZA ZA2023/11412A patent/ZA202311412B/en unknown
-
2024
- 2024-03-29 JP JP2024055230A patent/JP2024088689A/ja not_active Withdrawn
- 2024-07-19 UY UY0001040829A patent/UY40829A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513804A5 (enExample) | ||
| JP2018524001A5 (enExample) | ||
| JP2019523753A5 (enExample) | ||
| JP2022191383A5 (enExample) | ||
| JP2015146822A5 (enExample) | ||
| JP2020122013A5 (enExample) | ||
| JP2016053091A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2010506596A5 (enExample) | ||
| JP2019523221A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| HK1254357A1 (zh) | 特异性针对过度磷酸化t蛋白的抗体及其使用方法 | |
| JP2017522888A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| TN2018000419A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof. | |
| JP2014506790A5 (enExample) | ||
| JP2017532290A5 (enExample) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| JP2018521691A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2016515524A5 (enExample) | ||
| JP2012526542A5 (enExample) | ||
| JP2017537972A5 (enExample) | ||
| FI3390451T3 (fi) | Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan |